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A 91-year-old woman affected with acquired Von Willebrand (VW) syndrome and intestinal angiodysplasias presented
with severe gastrointestinal bleeding (hemoglobin 5 g/dl). Despite replacement therapy with VW factor/factor VIII
concentrate qid, bleeding did not stop (eleven packed red blood cell units were transfused over three days). High
circulating levels of anti-VW factor immunoglobulin M were documented immunoenzimatically. Heart ultrasound
showed abnormalities of the mitral and aortic valves with severe flow alterations. When intravenous immunoglobulins
were added to therapy, prompt clinical and laboratory responses occurred: complete cessation of bleeding, raise in
hemoglobin, VW factor antigen, VW ristocetin cofactor and factor VIII levels as well as progressive reduction of the
anti-VWF autoantibody levels.
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Von Willebrand factor (VWF) is an adhesive glycopro-
tein synthesized by endothelial cells and megacaryocytes
and released through a regulated pathway after storage
in endothelial Weibel-Palade bodies and platelet alpha
granules [1,2]. It circulates in plasma in large multimers
and plays a pivotal role in primary haemostasis as it me-
diates adhesion of platelets to the subendothelium at
sites of vascular damage [2]. The deficiency of VWF is
associated with a hemostatic disorder and can be quanti-
tative or qualitative [3]. It may be hereditary or acquired,
with the hereditary form being one of the most common
coagulation abnormalities in humans. In contrast, the
acquired form is rare and generally occurs in individuals
with no personal or family history of bleeding [3]. It is
characterized by a prolonged bleeding time and variably* Correspondence: massimo.cugno@unimi.it
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unless otherwise stated.low plasma levels of VWF and factor VIII, and is similar
to the inherited form in terms of laboratory findings and
clinical severity [4,5]. However, bleeding may be less pre-
dictable and more severe than in the congenital form. The
pathophysiology underlying acquired Von Willebrand
syndrome (VWS) is heterogeneous and none of the pro-
posed mechanisms appears to be disease-specific [3-5].
Most patients have low plasma levels of VWF because of
accelerated removal by three main mechanisms: 1) specific
or non-specific autoantibodies that form circulating im-
mune complexes with VWF and inactivate it (these com-
plexes are cleared by Fc-bearing cells); 2) absorption of
VWF onto malignant cell clones; 3) loss of high molecular
weight VWF multimers under conditions of high shear
stress [3-6]. Acquired VWS was first described in a patient
with systemic lupus erythematosus in 1968 [7]. Subse-
quently, more than 300 cases have been reported, but the
actual prevalence of the disease is underestimated because
most patients do not bleed until they are exposed to major
trauma or major invasive procedures and surgery [8].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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immune, lymphoproliferative and myeloproliferative dis-
orders, which account for 48–63% of cases; however, an
association with solid tumors, cardiovascular disorders
and hypothyroidism has also been described [9-13].
Treatment of acquired VWS is aimed to control acute
bleeding episodes, to prevent bleeding when an invasive
procedure is necessary, and when possible, to control
the underlying disease [14].
Acute bleeding can be treated with desmopressin
(DDAVP) and VWF/FVIII (factor VIII) concentrates or in
unresponsive patients with recombinant factor VII [14].
Therapeutic approaches aimed to contrast autoantibodies
include high-dose intravenous immunoglobulin, plasma-
pheresis, corticosteroids, and immunosuppressive drugs
[14-16]. In particular, the effectiveness of intravenous im-
munoglobulin was demonstrated in an open-label cross-
over study in patients with acquired VWS associated with
monoclonal gammopathy of undetermined significance of
the IgG class but not of the IgM class [17].
We report a case of acquired VWS with mixed origin
(autoimmune, due to anti-VWF IgM, and high shear
stress, due to mitral and aortic valve abnormalities) whose
severe and recurrent gastrointestinal bleeding was not
controlled by replacement therapy alone, but promptly
stopped after addition of high dose intravenous immuno-
globulins. The hemostatic improvement was associated
with a marked reduction in the clearance of VWF and
FVIII as well as with a progressive decrease in the titer of
anti-VWF autoantibody.
Case description
A 91-year-old woman with a diagnosis of acquired VWS
since the age of 86 was admitted to our hospital for se-
vere and recurrent gastrointestinal bleedings.
The patient had a history of a previous right nephrec-
tomy because of kidney stones at the age of 50, arterial
hypertension, permanent atrial fibrillation, pulmonary
chondromatous hamartoma diagnosed at the age of 72,
previous colonic cancer treated with left hemicolectomy
and locoregional lymphadenectomy at the age of 83. At
the beginning, the patient presented a mild bleeding
diathesis and was diagnosed with acquired VWS on
the basis of coagulation abnormalities: factor VIII co-
agulant activity (FVIII: C) was 10% of normal pooled
plasma, von Willebrand factor antigen (VWF Ag) was
7%, von Willebrand factor ristocetin cofactor (VWF:
Rco) was <6%. The patient was treated with courses of
factor VIII-rich VWF concentrate (FVIII concentrate/
vWF-Hemate P, CLS Behring, Marburg, Germany). In
the last 2 years, the patient underwent multiple hospitali-
zations for recurrent gastrointestinal bleedings due to
intestinal angiodysplasias, diagnosed by double balloon
enteroscopy. She was treated with blood transfusions,tranexamic acid, subcutaneous octreotide and FVIII/VWF
concentrates (Haemate P). During one of her past hospi-
talizations, because of poor clinical response, Haemate P
was also replaced by a high purity FVIII/VWF concentrate
(Alphanate (Grifols, Los Angeles, CA, USA) without im-
provement of bleeding control. An unsuccessful attempt
with atorvastatin was also done.
In the current hospitalization, on admission, the pa-
tient presented with abundant bright red blood in stool,
blood pressure was 110/65 mmHg, pulse rate was 80
beats per minute (irregular), respiratory rate was 25
breaths per minute and oxygen saturation was 97% when
breathing in air. On physical examination, bilateral lower
limb edema was present. A grade 2/6 systolic murmur
was heard at the mitral and aortic areas. Physical examin-
ation of chest and abdomen did not reveal any acute ab-
normality. Laboratory tests documented severe anemia
with a minimum hemoglobin value of 5.0 g/dl and an in-
crease in blood urea nitrogen (94 mg/dL). No additional
alterations of routine laboratory tests were observed; in
particular, activated partial thromboplastin time (aPTT),
lactate dehydrogenase (LDH), haptoglobin and bilirubin
were within the normal range and the Coombs test was
negative. The electrocardiogram showed atrial fibrillation
with normal intraventricular conduction and non specific
repolarization abnormalities. The chest X ray was negative
for parenchymal consolidations except for the known
hamartoma.
During hospitalization, the patient was treated with in-
fusion of octreotide (dose 25 μg/h) and replacement of
factor VIII/VWF (Hemate P 2000 IU, corresponding to
2000 IU of FVIII and 4800 IU of VWF, every 6 hours).
Although this therapy was continued, gastrointestinal
bleeding did not stop, and a total of eleven bags of
packed red blood cells were transfused over three days.
Contrast-enhanced CT scan of the abdomen and mes-
enteric vessel arteriography were performed without
finding any single source of active or recent gastrointes-
tinal bleeding.
An echocardiogram showed structural abnormalities
of the mitral valve (fibrosis and partial retraction of the
posterior leaflet and its support apparatus) and the aor-
tic valve (diffuse calcifications of the cusps with partial
coalescence of commissural margins); increased ortho-
grade flow gradients (mitral mean gradient of 8 mmHg
and peak aortic gradient of 19 mmHg). Sampling with
color-Doppler showed flow abnormalities: mild aortic re-
gurgitation with coaxial jet; severe mitral insufficiency
with eccentric jet, dispersed along the lateral wall of the
atrium (Coanda effect).
Laboratory investigation by means of an immunoenzy-
matic method showed high circulating levels of anti-VWF
IgM, whereas anti VWF IgG and IgA were negative.
Briefly, purified VWF (kindly provided by doctor Friedrich
Figure 1 Von Willebrand factor ristocetin cofactor (VWF:RCo) residual activity of normal pooled plasma incubated with different dilutions
of plasma from the patient with acquired von Willebrand syndrome (VWS) (Patient plasma) and plasma from another patient with acquired
VWS containing neutralizing anti-VWF autoantibodies (positive control).
Figure 2 Time course of haemoglobin concentration in peripheral
blood of the patient with acquired von Willebrand syndrome
before and after high dose immunoglobulin (Ig) infusion. Units of
packed red blood cells (PRBCs) which were transfused and replacement
therapy with Hemate P are reported.
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night onto microtitration plates and, after washing, the
wells were coated with bovine albumin to avoid non-
specific binding. After further washes, a 1:20 dilution of
the plasma samples was added and incubated for 45 minutes
at room temperature. After washing, the VWF-bound
immunoglobulins were identified by means of class-
specific mouse monoclonal antibodies, which were de-
tected by means of peroxidase-conjugated anti-mouse
immunoglobulin antibodies and revealed by orthophe-
nylenediamine. The results were expressed as absorb-
ance and referred to 20 normal subjects. The dilution
curve of anti-VWF IgM from patient plasma was linear
from 1500 to 200 absorbance (r = 0.999). The within-
and between-assay coefficients of variation were less
than 15%. By adaptation of the Bethesda method to
VWF, the autoantibody against VWF was demonstrated
to be non neutralizing (Figure 1). The presence of anti-
VWF in patient’s plasma suggested an autoimmune
origin of the bleeding disorder. For this reason, intra-
venous immunoglobulin (IVIg) was administered at a
dose of 0.4 g/Kg/day for 5 days with good clinical and
laboratory response (complete cessation of bleeding,
raise in hemoglobin as well as in FVIII and VW:RCo
plasma levels). In the 3 days before IVIg, due to the se-
vere bleeding, the patient was transfused with 11 units
of packed red blood cells (PRBCs) and her hemoglobin
levels remained below 6 g/dl whereas, after IVIg,
hemoglobin levels were stable at 10–11 g/dl without
need of transfusion (Figure 2). IVIg had a dramatic effect
on the kinetics of VWF:Ag, VWF:RCo and FVIII:C, indu-
cing a 3- to 4-fold increase in their peak and recovery
values after infusion of 2000 U of Hemate P (Figures 3, 4
and 5). Intravenous immunoglobulin also affected thelevels of anti-VWF autoantibodies which progressively
decreased reaching an 8-fold reduction 21 days later
(Figure 6). After IVIg treatment, a therapy with pred-
nisone (25 mg/day) and azathioprine (50 mg bid) was
started.
At discharge, the patient was in a good general status,
fecal occult blood test was negative and hemoglobin
levels were 11.7 g/dl. The discharge therapy consisted in
Hemate 2,000 IU tid, azathioprine 50 mg bid, omepra-
zole 20 mg bid and prednisone 25 mg/day.
Figure 3 Kinetics of von Willebrand factor antigen (VWF:Ag) in plasma of the patient with acquired von Willebrand syndrome after
replacement therapy with Hemate P. VWF:Ag levels were measured 2 days before and 2, 3 and 4 days after starting high dose intravenous
immunoglobulin (Ig) infusion.
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Our case report clearly shows that it is possible to stop
life-threatening bleeding in acquired VWS associated
with anti-VWF autoantibody by the infusion of high
dose IVIg in addition to replacement therapy with VWF/
FVIII concentrate. In our patient with acquired VWS as-
sociated with IgM autoantibodies against VWF and high
shear stress due to abnormalities of the mitral and aortic
cardiac valves, IVIg strikingly modified the kinetics of
VWF and FVIII with a 3 to 4 fold reduction in their
clearance. Moreover, we observed a progressive reduc-
tion of anti-VWF autoantibody titer which started justFigure 4 Kinetics of von Willebrand factor ristocetin cofactor (VWF:RCo
after replacement therapy with Hemate P. VWF:RCo levels were measur
intravenous immunoglobulin (Ig) infusion.after the beginning of IVIg therapy and continued after-
wards, almost reaching the upper limit of normal 21 days
later. Our data indicate that the anti VWF autoantibodies
of our patient, albeit non neutralizing, markedly increase
VWF/FVIII clearance, and high-dose IVIg may counter-
balance this effect by their immunomodulatory properties.
IVIg is not recommended for routine use in the treat-
ment of acquired VWS, according to evidence-based guide-
lines [18]. However, according to consensus by expert
panels, IVIg may be considered one option among adjunct-
ive therapies in urgent situations (eg, active bleeding or pre-
operatively) [18].) in plasma of the patient with acquired von Willebrand syndrome
ed 2 days before and 2, 3 and 4 days after starting high dose
Figure 5 Kinetics of factor VIII coagulant activity (FVIII:C) in plasma of the patient with acquired von Willebrand syndrome after
replacement therapy with Hemate P. Factor VIII:C levels were measured 2 days before and 2, 3 and 4 days after starting high dose
intravenous immunoglobulin (Ig) infusion.
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VWS associated with monoclonal gammopathy of un-
determined significance (MGUS), Federici et al. demon-
strated that the infusion of high-dose IVIg, in addition
to DDAVP and plasma FVIII/VWF concentrate, induces
transient (short-term therapy) and prolonged (long-term
therapy) clinical and laboratory remission in IgG-MGUS
but not in IgM-MGUS [17]. Maddox et al. reported suc-
cessful cystectomy for relapsed transitional cell bladder
carcinoma in a patient with acquired VWS and MGUSFigure 6 Plasma levels of anti von Willebrand factor (anti-VWF)
autoantibodies expressed as absorbance (Abs) at 492 nm in
plasma from the patient with acquired von Willebrand syndrome
before and after starting treatment with high dose intravenous
immunoglobulin (Ig). The dotted line represents the upper limit of
the normal range.treated with a combined therapy of plasma exchange,
high-dose IVIg and plasma FVIII/VWF concentrate [19].
Similarly, Eikenboom et al. obtained good clinical results
in a patient who underwent cholecystectomy because of
acute cholecystitis with perforation, using high-dose IVIg
and plasma FVIII/VWF concentrate [20]. Lipkind et al. re-
ported a pregnant woman with acquired VWS who under-
went successful delivery with intravenous dexamethasone,
FVIII/VWF concentrate and high-dose IVIg [21]. Kanakry
and Gladstone reported the case of an 84-year-old man
without a personal or family history of bleeding diathesis
who underwent resection of a duodenal villous adenoma
and developed a life-threatening gastrointestinal bleed. A
diagnosis of acquired VWS was established and the pa-
tient was treated with high-dose IVIg obtaining the stop
of bleeding within 48 hours. One month after IVIg, he
was treated with rituximab for four weekly doses followed
by eight doses of maintenance, and no further bleeding
occurred [22].
Our results are in agreement with these observations
and indicate the importance of the autoantibodies
against VWF in the pathogenesis of the bleeding compli-
cations in acquired VWS by their marked effect on the
kinetics of VWF and FVIII. The dramatic efficacy of
high-dose IVIg in stopping the gastrointestinal life
threatening bleeding further supports this view.
The prompt hemostatic response after IVIg administra-
tion may be due to rapid saturation of Fc receptors on
cells of the mononuclear phagocyte system by the infused
Ig, thus avoiding the clearance of autoantibody-VWF
immunocomplexes [23]. Since the autoantibody of our pa-
tient has been demonstrated to be non neutralizing, it is
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complex maintains its normal function. In addition,
anti-idiotypic antibodies contained in IVIg may block
the activity of pathogenic autoantibodies, thus contrib-
uting to the therapeutic effect observed in several
antibody-dependent pathologies [24]. Finally, IVIg effi-
cacy may be due to other non-exclusive actions on mul-
tiple pathways which, although poorly defined, can
open new perspectives in the treatment of a growing
number of autoimmune diseases [24-26].
The progressive decrease in the titer of anti-VWF
autoantibody may be due to the effect of IVIg on human
B cells. It was shown that IVIg promotes increased Fc
receptor expression on plasma cells which may stimulate
their sensitivity to apoptosis and have a direct impact on
autoantibody production [27,28]. The immunosuppres-
sive therapy with prednisone and azathioprine which
was started after IVIg therapy, may have contributed to
the decrease in the titer of anti-VWF autoantibody.
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